EDGC Develops AI-Based Multi-Omics Platform for Accurate Cancer Diagnosis
September 21, 2023
Seoul, South Korea – EDGC (Eone Diagnomics) announced today the groundbreaking results of their study on cancer diagnosis, showcasing the significant accuracy improvement achieved through their state-of-the-art multi-omics genome analysis platform powered by artificial intelligence (AI) technology.
Thanks to advancements in AI, the medical community is on the verge of a game-changing era where the early detection of cancer could be as simple as a single drop of blood.
The research findings, published in the esteemed international scientific journal Cancers, present a comprehensive study conducted by EDGC that has revolutionized the accuracy of cancer diagnosis. The publication, titled ‘Improving Lung Cancer Classification by Integrating Liquid Biopsy Multi-Omic Data with Machine Learning Techniques,’ showcases the culmination of EDGC’s extensive research efforts in developing advanced cancer diagnostic solutions.
According to the paper, the proprietary AI-based multi-omics platform developed by EDGC demonstrated superior accuracy compared to conventional independent cancer diagnostic methods. While traditional cell-free DNA (cfDNA) diagnostic methods achieved an AUC (Area Under the Curve) level of only 0.7, gene copy number (CNV) diagnostic methods reached 0.8, and cancer marker diagnostic methods recorded levels below 0.7, EDGC’s integration of independent artificial intelligence analysis improved accuracy to an impressively high AUC of 0.931. This breakthrough means that lung cancer patients can now be distinguished from healthy individuals with a 93% probability, marking a significant advancement in the field of cancer diagnosis.
Equally noteworthy, the EDGC multi-omics analysis method can also differentiate between early-stage and late-stage lung cancer patients. The accuracy of identifying early-stage lung cancer patients (stage 1 and 2) using the EDGC multi-omics analysis achieved an AUC of 0.964, while for late-stage lung cancer patients (stage 3 and 4), the platform exhibited an astonishing AUC of 0.983. This translates to a 96.4% and 98.3% probability, respectively, of diagnosing early and terminal cancer patients accurately. The potential for early cancer detection through the EDGC multi-omics analysis represents a significant breakthrough, solidifying EDGC’s position as a leader in cancer diagnostic technology.
Currently, EDGC offers its OncoCatch-S technology, as featured in the published paper, in Germany, Panama, Turkey, and Vietnam. The company plans to gradually expand its presence in the countries it operates in. OncoCatch-S is a comprehensive lung cancer diagnosis multi-omics platform that integrates the analysis of cancer markers, cell-free DNA (cfDNA) concentration, and gene copy number variation (CNV).
OncoCatch EDGC employs Next Generation Sequencing (NGS) technology and advanced bioinformatics to analyze tumor DNA circulating in the blood. This groundbreaking technology enables the early detection of cancer, monitoring for cancer recurrence, and personalized selection of targeted anticancer drugs. OncoCatch encompasses four distinct pipelines: OncoCatch-E, OncoCatch-S, OncoCatch-CDx, and OncoCatch-M, each tailored to specific diagnostic purposes and methods.
- OncoCatch-E: This pipeline facilitates the detection of circulating tumor DNA derived from cancer cells present in trace amounts within cell-free DNA (cfDNA). By measuring methylation patterns, which are epigenetic changes associated with cancer development, and employing artificial intelligence algorithms, multiple types of cancer can be screened at an early stage.
- OncoCatch-CDx: Designed to support medical professionals, OncoCatch-CDx provides customized anticancer drug prescriptions for all types of solid cancer, catering to the unique needs of individual cancer patients.
- OncoCatch-M: Serving as a premium service, OncoCatch-M monitors cancer recurrence, metastasis, and evaluates the efficacy of anticancer treatments, empowering medical experts with crucial insights to make informed decisions.
Lee Min-seop, CEO of EDGC, expressed his enthusiasm for the unique capabilities of OncoCatch, stating, “Our diagnostic technology not only enables the early detection of cancer but also increases the survival rate of patients while reducing treatment costs. We are committed to delivering exceptional services and investing our efforts in research to fulfill this purpose.”
Contact:
007@newspim.com
Industry | 2023.09.21 09:14
[서울=뉴스핌] Reporter Lee Young-gi = EDGC (Eone Diagnomics) on the 21st announced the results of a study that dramatically improved the accuracy of cancer diagnosis using a multi-omics genome analysis platform based on AI technology.
With the development of AI technology, an era when it is possible to detect cancer early with a single drop of blood is expected to open.
The results of the research were published in the September issue of Cancers, a journal listed in the international science and technology reference index SCIE (Science Citation Index Expended). The title of this paper is ‘Improving Lung Cancer Classification by Integrating Liquid Biopsy Multi-Omic Data with Machine Learning Techniques’, and it is a paper that EDGC has developed over a long period of research to diagnose cancer. We presenting research results that have dramatically improved accuracy.
According to this paper, the accuracy of cancer analysis through EDGC’s proprietary artificial intelligence multi-omics platform recorded higher accuracy compared to independent cancer diagnosis methods. A cell-free DNA (cfDNA) diagnostic method was only recorded at an AUC level of 0.7, a gene copy number (CNV) diagnostic method was only recorded at an AUC level of 0.8, and a cancer marker diagnostic method was only recorded below an AUC level of 0.7, but ‘to integrate with EDGC’s independent artificial intelligence The accuracy of its analysis improved to AUC 0.931. This figure means that lung cancer patients can be distinguished from normal people with a probability of about 93%. This is a very high accuracy in the field of cancer diagnosis and is considered a breakthrough cancer diagnosis technology.
It is also worth noting that this technology can differentiate between patients with early stage lung cancer and those with late stage lung cancer. The EDGC multi-omics analysis method can differentiate between early stage lung cancer patients (stage 1 and 2) with an accuracy of AUC 0.964, and late stage lung cancer patients (stage 3 and 4) with a high accuracy of AUC 0.983. This means that early and terminal cancer patients can be diagnosed with a probability of approximately 96.4% and 98.3%. Early detection of cancer is possible through the EDGC multi-omics analysis method. EDGC attracts international attention by proving the high technological capability of EDGC with the research results of this multi-omics analysis method developed exclusively with the institute’s own technology.
EDGC currently serves the OncoCatch-S technology presented in the paper in Germany, Panama, Turkey and Vietnam, and plans to gradually expand its presence in the countries in which it operates. The Onco Catch-S Service is a lung cancer diagnosis multi-omics platform that integrates analysis of cancer markers, cell-free DNA (cfDNA) concentration, and gene copy number variation (CNV).
OncoCatch EDGC is a technology that analyzes tumor DNA circulating in the blood using NGS (Next Generation Sequencing) technology and advanced bioinformatics technology. It can be used to detect cancer early, check for cancer recurrence, and select tailored targeted anticancer drugs. OncoCatch has four pipelines: OncoCatch-E, OncoCatch-S, OncoCatch-CDx, and OncoCatch-M, depending on the purpose and method of inspection.
OncoCatch-E can detect circulating tumor DNA derived from cancer cells that exists in trace amounts in cell-free DNA (cfDNA). It is possible to measure methylation patterns, which are epigenetic changes associated with the development of cancer, and by applying artificial intelligence algorithms, multiple cancers can be screened at a very early stage. OncoCatch-CDx supports medical staff with customized anticancer drug prescriptions for all types of solid cancer for cancer patients. OncoCatch-M is a premium service that monitors cancer recurrence, metastasis, and determines the effectiveness of anticancer treatment.
Lee Min-seop, CEO of EDGC, said, “OncoCatch is a very distinctive diagnostic technology in that it can detect cancer early, increase the survival rate of patients, and reduce treatment costs.” “We intend to deliver services and focus our capabilities on research for this purpose,” he said.
007@newspim.com
#EDGC #unveils #technology #dramatically #improves #accuracy #cancer #diagnosis #global #cancer #journal
